Elevated tauopathy and alpha-synuclein pathology in postmortem Parkinson's disease brains with and without dementia
about
α-Synuclein modifies huntingtin aggregation in living cellsCerebrospinal Fluid Amyloid β1-42, Tau, and Alpha-Synuclein Predict the Heterogeneous Progression of Cognitive Dysfunction in Parkinson's DiseasePathogenesis of synaptic degeneration in Alzheimer's disease and Lewy body diseaseCSF tau and tau/Aβ42 predict cognitive decline in Parkinson's diseaseAge-dependent effects of A53T alpha-synuclein on behavior and dopaminergic functionGSK-3β dysregulation contributes to parkinson's-like pathophysiology with associated region-specific phosphorylation and accumulation of tau and α-synucleinThe protease Omi regulates mitochondrial biogenesis through the GSK3β/PGC-1α pathwayAlpha-synuclein and tau: teammates in neurodegeneration?Selective binding of nuclear alpha-synuclein to the PGC1alpha promoter under conditions of oxidative stress may contribute to losses in mitochondrial function: implications for Parkinson's diseaseCerebrospinal fluid amyloid β and tau in LRRK2 mutation carriersTau deposition drives neuropathological, inflammatory and behavioral abnormalities independently of neuronal loss in a novel mouse modelAssociation of cerebrospinal fluid β-amyloid 1-42, T-tau, P-tau181, and α-synuclein levels with clinical features of drug-naive patients with early Parkinson disease.Reduction of RPT6/S8 (a Proteasome Component) and Proteasome Activity in the Cortex is Associated with Cognitive Impairment in Lewy Body DementiaParkinson's disease-implicated kinases in the brain; insights into disease pathogenesis.Oxidation and nitration in dopaminergic areas of the prefrontal cortex from patients with bipolar disorder and schizophreniaPhosphorylation of NBR1 by GSK3 modulates protein aggregation.Region-specific tauopathy and synucleinopathy in brain of the alpha-synuclein overexpressing mouse model of Parkinson's diseaseTau enhances α-synuclein aggregation and toxicity in cellular models of synucleinopathy.Tau reduction does not prevent motor deficits in two mouse models of Parkinson's diseaseParaquat, but not maneb, induces synucleinopathy and tauopathy in striata of mice through inhibition of proteasomal and autophagic pathwaysIntranasal NAP (davunetide) decreases tau hyperphosphorylation and moderately improves behavioral deficits in mice overexpressing α-synuclein.From model system to clinical medicine: pathophysiologic links of common proteinopathies.Enhancing nucleotide metabolism protects against mitochondrial dysfunction and neurodegeneration in a PINK1 model of Parkinson's diseaseA powerful yeast model to investigate the synergistic interaction of α-synuclein and tau in neurodegeneration.Tauopathic changes in the striatum of A53T α-synuclein mutant mouse model of Parkinson's disease.Hyperphosphorylated Tau in an α-synuclein-overexpressing transgenic model of Parkinson's disease.Identification of the sites of tau hyperphosphorylation and activation of tau kinases in synucleinopathies and Alzheimer's diseases.GSK-3 in Neurodegenerative Diseases.CSF biomarkers and clinical progression of Parkinson disease.α-Synuclein modifies mutant huntingtin aggregation and neurotoxicity in Drosophila.The Docosanoid Neuroprotectin D1 Induces TH-Positive Neuronal Survival in a Cellular Model of Parkinson's DiseaseLow doses of single or combined agrichemicals induces α-synuclein aggregation in nigrostriatal system of mice through inhibition of proteasomal and autophagic pathways.Parkinson disease and progressive supranuclear palsy: protein expression in skin.Combining Dopaminergic Facilitation with Robot-Assisted Upper Limb Therapy in Stroke Survivors: A Focused ReviewLongitudinal assessment of tau and amyloid beta in cerebrospinal fluid of Parkinson diseaseCSF biomarkers associated with disease heterogeneity in early Parkinson's disease: the Parkinson's Progression Markers Initiative study.Gsk3β and Tomm20 are substrates of the SCFFbxo7/PARK15 ubiquitin ligase associated with Parkinson's disease.Dopamine Cytotoxicity Involves Both Oxidative and Nonoxidative Pathways in SH-SY5Y Cells: Potential Role of Alpha-Synuclein Overexpression and Proteasomal Inhibition in the Etiopathogenesis of Parkinson's DiseaseNeuropathology of sporadic Parkinson's disease: evaluation and changes of concepts.Interaction between pathogenic proteins in neurodegenerative disorders.
P2860
Q24298430-3A57E00F-BE5E-4E51-81D7-07902FBA8128Q26744782-6010741E-FB80-4B8E-9E89-2AB5A4500D3DQ26853610-B93F075A-3700-4DC9-9BF1-8582AD4B3DCAQ27304608-7BB02DB3-7C66-4421-ADC6-1EED6324A270Q27330366-53C46622-FE19-4183-BCE8-8F3772DC9074Q27331743-5300F2CA-A46D-4137-A528-1E252A8802B9Q28117215-8B4F1245-ABDC-4CB6-80B6-97998D5A9506Q28250508-DFFCAD90-60E7-4D4A-9291-74D7CC8E5CB7Q28576367-1EA9F893-5D27-4BD3-89F1-A6FB12A470C2Q30525550-EEC27BD1-7A8D-4E31-A078-BF6BDFD645C3Q30667424-A8C9EC26-01B0-4859-8540-FB8D840C31B8Q33666297-953477DB-65CD-4B9A-8E8B-1667198F0BE0Q33708946-EDD71D3E-358B-4BF6-8B49-3F41EE0F100EQ33797449-72731C7D-6215-4B25-B945-4907B7027CF4Q33817921-51F21EFD-7663-42DF-A148-2E8216E94CBBQ33878926-FCFC0D5F-5448-4CE9-A8DE-07E9C982F997Q33980640-4CC76299-37ED-4E4E-943E-91F64F1C1512Q34062509-1B315D17-D3CD-4335-AE16-CC30A1CC7572Q34113712-080F303C-4287-4607-9AAE-0F3B674F0BCBQ34146349-97A1F77E-BB3B-4C97-88B1-70F02C922D6BQ34292532-39388A1D-EFB5-4281-A938-445D6A1F9FFEQ34318017-7380623C-5E50-4559-B7C0-797FE55F711DQ34348591-6697776E-88B6-4A6F-8341-9045B3D830EBQ34581042-F6AA5E94-E607-484B-BC9A-0C0FB32C1642Q34704153-90934997-48C4-46E9-8A88-02BA0C459836Q34917354-398CA22E-9F5D-4BCE-B6BA-D87522D0D8C5Q35000764-0D5C1408-983F-4353-AD04-B506E752A074Q35001040-BAC4CF08-FB26-410C-BF6D-3F7C8F12F145Q35106542-B42BFB25-F9C5-4885-96A3-B77AC0323940Q35163459-F8AC3B1D-F561-4F79-B7BC-79D1EB1B47CAQ36149449-5E76F206-FDBF-4DB0-87A4-A2953707A9ACQ36492769-3C87A949-2CCC-4965-9194-20AEC0FBD091Q36639646-036F522D-7581-4985-B0A1-FF23DD5B839FQ36900126-9B1F6F30-6A70-4845-99D0-7BDFBE3013B4Q37228718-C120C498-0880-4406-8E2B-79A465CA8B03Q37272860-C7996279-DE36-47A3-B258-1F477644549CQ37603383-730CF366-CD38-4B3D-B547-7319C8770192Q37717851-8F1713AA-076A-402E-9AEF-92A28091FED8Q37955871-CF3DEB7D-123E-45AF-A85B-5F9D264859E1Q37969262-54CCBAF8-445F-4BEF-91AE-5EFAAEDAFFF8
P2860
Elevated tauopathy and alpha-synuclein pathology in postmortem Parkinson's disease brains with and without dementia
description
2010 nî lūn-bûn
@nan
2010 թուականի Յունիսին հրատարակուած գիտական յօդուած
@hyw
2010 թվականի հունիսին հրատարակված գիտական հոդված
@hy
2010年の論文
@ja
2010年論文
@yue
2010年論文
@zh-hant
2010年論文
@zh-hk
2010年論文
@zh-mo
2010年論文
@zh-tw
2010年论文
@wuu
name
Elevated tauopathy and alpha-s ...... ains with and without dementia
@ast
Elevated tauopathy and alpha-s ...... ains with and without dementia
@en
Elevated tauopathy and alpha-s ...... ains with and without dementia
@nl
type
label
Elevated tauopathy and alpha-s ...... ains with and without dementia
@ast
Elevated tauopathy and alpha-s ...... ains with and without dementia
@en
Elevated tauopathy and alpha-s ...... ains with and without dementia
@nl
prefLabel
Elevated tauopathy and alpha-s ...... ains with and without dementia
@ast
Elevated tauopathy and alpha-s ...... ains with and without dementia
@en
Elevated tauopathy and alpha-s ...... ains with and without dementia
@nl
P2093
P2860
P921
P1476
Elevated tauopathy and alpha-s ...... ains with and without dementia
@en
P2093
Anita Sidhu
Jeffrey N Joyce
Jessica Jones
Jonathan Wills
Thomas Haggerty
Valeriy Duka
P2860
P304
P356
10.1016/J.EXPNEUROL.2010.06.017
P407
P577
2010-06-28T00:00:00Z